Medtronic to pay $260m for stomach pacing firm
This article was originally published in Clinica
Medtronic has agreed to pay $260m up front for Transneuronix, a company that has developed electrical stimulation technology to treat obesity. Additional payments will be made based on set revenue objectives.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.